Jill M. Broadfoot
2019 - aTYR PHARMA
In 2019, Jill M. Broadfoot earned a total compensation of $454.6K as Chief Financial Officer at aTYR PHARMA, a 36% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $59,500 |
|---|---|
| Option Awards | $20,600 |
| Salary | $350,000 |
| Stock Awards | $12,930 |
| Other | $11,594 |
| Total | $454,624 |
Broadfoot received $350K in salary, accounting for 77% of the total pay in 2019.
Broadfoot also received $59.5K in non-equity incentive plan, $20.6K in option awards, $12.9K in stock awards and $11.6K in other compensation.
Rankings
In 2019, Jill M. Broadfoot's compensation ranked 12,018th out of 13,971 executives tracked by ExecPay. In other words, Broadfoot earned more than 14.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 12,018 out of 13,971 | 14th |
Division Manufacturing | 4,872 out of 5,701 | 15th |
Major group Chemicals And Allied Products | 1,922 out of 2,200 | 13th |
Industry group Drugs | 1,657 out of 1,886 | 12th |
Industry Biological Products, Except Diagnostic Substances | 356 out of 389 | 9th |
Source: SEC filing on April 2, 2020.
Broadfoot's colleagues
We found two more compensation records of executives who worked with Jill M. Broadfoot at aTYR PHARMA in 2019.
News
aTYR PHARMA CEO Sanjay Shukla's 2023 pay falls 46% to $1.3M
April 5, 2024
aTYR PHARMA CEO Sanjay Shukla's 2021 pay jumps 75% to $1.9M
March 22, 2022
aTYR PHARMA CEO Sanjay Shukla's 2020 pay jumps 63% to $1.1M
March 23, 2021
aTYR PHARMA CEO Sanjay Shukla's 2019 pay falls 52% to $664K
April 2, 2020
aTYR PHARMA CEO Sanjay Shukla's 2018 pay falls 36% to $1.4M
March 28, 2019